The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Tufan Erginbilgiç's four pillars involved showing employees the extent of Rolls-Royce's issues, then giving them a say in ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration (“HRSA”), an administrative agency under ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...